Market Access Reality Check for Disease Modifying AD Drugs

• CMS coverage gap for pre clinical anti amyloids and spill over to private payers
• Cost drivers: MRI monitoring, infusion logistics and diagnostic bundling
• Generating evidence packages that HTA bodies prioritise (QoL, caregiver, budget impact) with responsible data storytelling to maintain policymaker trust

Speakers:

Laura Cohen

Vice President

Eli Lilly & Co.